Swen Hesse1,2, Georg-Alexander Becker3, Michael Rullmann3,4,5, Anke Bresch3, Julia Luthardt3, Mohammed K Hankir4, Franziska Zientek4, Georg Reißig4, Marianne Patt3, Katrin Arelin5,6, Donald Lobsien7, Ulrich Müller8, S Baldofski4,9, Philipp M Meyer3, Matthias Blüher10, Mathias Fasshauer4,10, Wiebke K Fenske4, Michael Stumvoll4,10, Anja Hilbert4,9, Yu-Shin Ding11, Osama Sabri3,4. 1. Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany. swen.hesse@medizin.uni-leipzig.de. 2. Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany. swen.hesse@medizin.uni-leipzig.de. 3. Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany. 4. Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany. 5. Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany. 6. Day Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany. 7. Department of Neuroradiology, University of Leipzig, Leipzig, Germany. 8. Department of Psychiatry and Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK. 9. Department of Medical Psychology and Medical Sociology, University of Leipzig, Leipzig, Germany. 10. Department of Internal Medicine, University of Leipzig, Leipzig, Germany. 11. Departments of Radiology and Psychiatry, New York University School of Medicine, New York, NY, USA.
Abstract
PURPOSE: The brain noradrenaline (NA) system plays an important role in the central nervous control of energy balance and is thus implicated in the pathogenesis of obesity. The specific processes modulated by this neurotransmitter which lead to obesity and overeating are still a matter of debate. METHODS: We tested the hypothesis that in vivo NA transporter (NAT) availability is changed in obesity by using positron emission tomography (PET) and S,S-[11C]O-methylreboxetine (MRB) in twenty subjects comprising ten highly obese (body mass index BMI > 35 kg/m2), metabolically healthy, non-depressed individuals and ten non-obese (BMI < 30 kg/m2) healthy controls. RESULTS: Overall, we found no significant differences in binding potential (BPND) values between obese and non-obese individuals in the investigated brain regions, including the NAT-rich thalamus (0.40 ± 0.14 vs. 0.41 ± 0.18; p = 0.84) though additional discriminant analysis correctly identified individual group affiliation based on regional BPND in all but one (control) case. Furthermore, inter-regional correlation analyses indicated different BPND patterns between both groups but this did not survive testing for multiple comparions. CONCLUSIONS: Our data do not find an overall involvement of NAT changes in human obesity. However, preliminary secondary findings of distinct regional and associative patterns warrant further investigation.
PURPOSE: The brain noradrenaline (NA) system plays an important role in the central nervous control of energy balance and is thus implicated in the pathogenesis of obesity. The specific processes modulated by this neurotransmitter which lead to obesity and overeating are still a matter of debate. METHODS: We tested the hypothesis that in vivo NA transporter (NAT) availability is changed in obesity by using positron emission tomography (PET) and S,S-[11C]O-methylreboxetine (MRB) in twenty subjects comprising ten highly obese (body mass index BMI > 35 kg/m2), metabolically healthy, non-depressed individuals and ten non-obese (BMI < 30 kg/m2) healthy controls. RESULTS: Overall, we found no significant differences in binding potential (BPND) values between obese and non-obese individuals in the investigated brain regions, including the NAT-rich thalamus (0.40 ± 0.14 vs. 0.41 ± 0.18; p = 0.84) though additional discriminant analysis correctly identified individual group affiliation based on regional BPND in all but one (control) case. Furthermore, inter-regional correlation analyses indicated different BPND patterns between both groups but this did not survive testing for multiple comparions. CONCLUSIONS: Our data do not find an overall involvement of NAT changes in humanobesity. However, preliminary secondary findings of distinct regional and associative patterns warrant further investigation.
Entities:
Keywords:
Noradrenaline; Noradrenaline transporter; Obesity; PET; PET imaging
Authors: J Melasch; M Rullmann; A Hilbert; J Luthardt; G A Becker; M Patt; A Villringer; K Arelin; P M Meyer; D Lobsien; Y-S Ding; K Müller; O Sabri; S Hesse; B Pleger Journal: Int J Obes (Lond) Date: 2015-10-20 Impact factor: 5.095
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Sulay Tovar; Lars Paeger; Simon Hess; Donald A Morgan; A Christine Hausen; Hella S Brönneke; Brigitte Hampel; P Justus Ackermann; Nadine Evers; Hildegard Büning; F Thomas Wunderlich; Kamal Rahmouni; Peter Kloppenburg; Jens C Brüning Journal: Cell Metab Date: 2013-09-03 Impact factor: 27.287
Authors: Swen Hesse; Peter Brust; Peter Mäding; Georg-Alexander Becker; Marianne Patt; Anita Seese; Dietlind Sorger; Jörg Zessin; Philipp M Meyer; Donald Lobsien; Sven Laudi; Bernd Habermann; Frank Füchtner; Julia Luthardt; Anke Bresch; Jörg Steinbach; Osama Sabri Journal: Eur J Nucl Med Mol Imaging Date: 2012-02-17 Impact factor: 9.236
Authors: Jonas Hannestad; Jean-Dominique Gallezot; Beata Planeta-Wilson; Shu-Fei Lin; Wendol A Williams; Christopher H van Dyck; Robert T Malison; Richard E Carson; Yu-Shin Ding Journal: Biol Psychiatry Date: 2010-08-05 Impact factor: 13.382
Authors: Thomas Vanicek; Marie Spies; Christina Rami-Mark; Markus Savli; Anna Höflich; Georg S Kranz; Andreas Hahn; Alexandra Kutzelnigg; Tatjana Traub-Weidinger; Markus Mitterhauser; Wolfgang Wadsak; Marcus Hacker; Nora D Volkow; Siegfried Kasper; Rupert Lanzenberger Journal: JAMA Psychiatry Date: 2014-12-01 Impact factor: 21.596
Authors: J Marvin Soeder; Julia Luthardt; Michael Rullmann; Georg A Becker; Mohammed K Hankir; Marianne Patt; Philipp M Meyer; Tatjana Schütz; Yu-Shin Ding; Anja Hilbert; Arne Dietrich; Osama Sabri; Swen Hesse Journal: Obes Surg Date: 2021-08-19 Impact factor: 3.479
Authors: Daniel Martins; Mattia Veronese; Federico E Turkheimer; Matthew A Howard; Steve C R Williams; Ottavia Dipasquale Journal: Brain Commun Date: 2021-12-22
Authors: Matthias Kirschner; Boris C Bernhardt; Bo-Yong Park; Valeria Kebets; Sara Larivière; Meike D Hettwer; Casey Paquola; Daan van Rooij; Jan Buitelaar; Barbara Franke; Martine Hoogman; Lianne Schmaal; Dick J Veltman; Odile A van den Heuvel; Dan J Stein; Ole A Andreassen; Christopher R K Ching; Jessica A Turner; Theo G M van Erp; Alan C Evans; Alain Dagher; Sophia I Thomopoulos; Paul M Thompson; Sofie L Valk Journal: Commun Biol Date: 2022-09-27
Authors: Juergen Dukart; Stefan Holiga; Michael Rullmann; Rupert Lanzenberger; Peter C T Hawkins; Mitul A Mehta; Swen Hesse; Henryk Barthel; Osama Sabri; Robert Jech; Simon B Eickhoff Journal: Hum Brain Mapp Date: 2020-10-20 Impact factor: 5.038